{"DataElement":{"publicId":"6133609","version":"1","preferredName":"Genetic Disorder Diagnosis Type","preferredDefinition":"Text term used to describe clinically diagnosed  genetic diseases or disorders.","longName":"genetic_syndrome_diagnosis","context":"GDC","contextVersion":"1","DataElementConcept":{"publicId":"6133601","version":"1","preferredName":"Genetic Disorder Diagnosis","preferredDefinition":"Genetic diseases are diseases in which inherited genes predispose to increased risk. The genetic disorders associated with cancer often result from an alteration or mutation in a single gene. The diseases range from rare dominant cancer family syndrome to familial tendencies in which low-penetrance genes may interact with other genes or environmental factors to induce cancer. Research may involve clinical, epidemiologic, and laboratory studies of persons, families, and populations at high risk of these disorders._The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","longName":"3133968v1.0:2239981v1.0","context":"GDC","contextVersion":"1","ObjectClass":{"publicId":"3133968","version":"1","preferredName":"Genetic Disorder","preferredDefinition":"Genetic Diseases are diseases in which inherited genes predispose to increased risk.  The genetic disorders associated with cancer often result from an alteration or mutation in a single gene.  The diseases range from rare dominant cancer family syndrome to familial tendencies in which low-penetrance genes may interact with other genes or environmental factors to induce cancer.  Research may involve clinical, epidemiologic, and laboratory studies of persons, families, and populations at high risk of these disorders.","longName":"C3101","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Genetic Disorder","conceptCode":"C3101","definition":"Genetic diseases are diseases in which inherited genes predispose to increased risk. The genetic disorders associated with cancer often result from an alteration or mutation in a single gene. The diseases range from rare dominant cancer family syndrome to familial tendencies in which low-penetrance genes may interact with other genes or environmental factors to induce cancer. Research may involve clinical, epidemiologic, and laboratory studies of persons, families, and populations at high risk of these disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EDA0818-6C4B-DE57-E040-BB89AD433F22","latestVersionIndicator":"Yes","beginDate":"2010-08-27","endDate":null,"createdBy":"WHITES","dateCreated":"2010-08-27","modifiedBy":"ONEDATA","dateModified":"2010-08-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2239981","version":"1","preferredName":"Diagnosis","preferredDefinition":"The process of identifying a disease by the signs and symptoms.","longName":"C15220","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Diagnosis","conceptCode":"C15220","definition":"The investigation, analysis and recognition of the presence and nature of disease, condition, or injury from expressed signs and symptoms; also, the scientific determination of any kind; the concise results of such an investigation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FD4EEB-1C71-0B27-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-26","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-06-26","modifiedBy":"ONEDATA","dateModified":"2005-06-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"GDC:NCI Genomic Data Commons","workflowStatus":"RELEASED","registrationStatus":"Application","id":"67656542-166B-5570-E053-F662850AD4CF","latestVersionIndicator":"Yes","beginDate":"2018-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-14","modifiedBy":"COOPERM","dateModified":"2020-08-17","changeDescription":"Created for caDSR Requests Q12018 Dictionary Updates for Review 3.8.18 mc","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6001793","version":"1","preferredName":"Genetic Disorder Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"6001793v1.0","context":"OCG","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Lynch syndrome","valueDescription":"Hereditary Non-Polyposis Colon Cancer","ValueMeaning":{"publicId":"2716424","version":"1","preferredName":"Hereditary Non-Polyposis Colon Cancer","longName":"2716424","preferredDefinition":"An autosomal dominant hereditary neoplastic syndrome characterized by the development of colorectal carcinoma and a high risk of developing endometrial carcinoma, gastric carcinoma, ovarian carcinoma, renal pelvis carcinoma, and small intestinal carcinoma.  Patients often develop colorectal carcinomas at an early age (mean, 45 years).  In the majority of the cases the lesions arise from the proximal colon.  At the molecular level, high-frequency microsatellite instability is present.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lynch Syndrome","conceptCode":"C8494","definition":"An autosomal dominant hereditary neoplastic syndrome characterized by the development of colorectal carcinoma and a high risk of developing endometrial carcinoma, gastric carcinoma, ovarian carcinoma, renal pelvis carcinoma, and small intestinal carcinoma. Patients often develop colorectal carcinomas at an early age (mean, 45 years). In the majority of the cases the lesions arise from the proximal colon. At the molecular level, high-frequency microsatellite instability is present.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"41B659B0-44F3-5521-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"REEVESD","dateCreated":"2007-12-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B49F37E-E089-074D-E053-F662850AC0B0","beginDate":"2017-10-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-10-11","modifiedBy":"ONEDATA","dateModified":"2017-10-11","deletedIndicator":"No"},{"value":"Li-Fraumeni syndrome","valueDescription":"Li-Fraumeni Syndrome","ValueMeaning":{"publicId":"3211225","version":"1","preferredName":"Li-Fraumeni Syndrome","longName":"3211225","preferredDefinition":"An autosomal dominant hereditary neoplastic syndrome caused by an alteration in the p53 tumor suppressor gene.  It is characterized by the development of malignant neoplasms at various anatomic sites.  The malignant neoplasms associated with Li-Fraumeni syndrome include adrenal cortex carcinoma, astrocytic tumors, colorectal carcinoma, gastric carcinoma, malignant breast neoplasms, medulloblastoma, osteosarcoma, and soft tissue sarcomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Li-Fraumeni Syndrome","conceptCode":"C3476","definition":"An autosomal dominant cancer predisposition syndrome caused by germline mutations of the TP53 gene. It is associated with breast carcinoma, choroid plexus carcinoma, adrenal cortex carcinoma, astrocytic tumors, medulloblastoma, soft tissue sarcoma, osteosarcoma, and leukemia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-DF6B-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B49F37E-E09F-074D-E053-F662850AC0B0","beginDate":"2017-10-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-10-11","modifiedBy":"ONEDATA","dateModified":"2017-10-11","deletedIndicator":"No"},{"value":"Fanconi anemia","valueDescription":"Fanconi Anemia","ValueMeaning":{"publicId":"5651022","version":"1","preferredName":"Fanconi Anemia","longName":"5651022","preferredDefinition":"A rare inherited disorder in which the bone marrow does not make blood cells. It is usually diagnosed in children between 2 and 15 years old. Symptoms include frequent infections, easy bleeding, and extreme tiredness. People with Fanconi anemia may have a small skeleton and brown spots on the skin. They also have an increased risk of developing certain types of cancer.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fanconi Anemia","conceptCode":"C62505","definition":"An autosomal recessive genetic disorder characterized by bone marrow failure, skeletal abnormalities, and an increased incidence of the development of neoplasias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"479020AD-0CB9-3909-E053-F662850A62CA","latestVersionIndicator":"Yes","beginDate":"2017-02-02","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2017-02-02","modifiedBy":"KUMMEROA","dateModified":"2023-04-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B49F37E-E094-074D-E053-F662850AC0B0","beginDate":"2017-10-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-10-11","modifiedBy":"ONEDATA","dateModified":"2017-10-11","deletedIndicator":"No"},{"value":"Gorlin syndrome","valueDescription":"Nevoid Basal Cell Carcinoma Syndrome","ValueMeaning":{"publicId":"3210902","version":"1","preferredName":"Nevoid Basal Cell Carcinoma Syndrome","longName":"3210902","preferredDefinition":"An autosomal dominant genetic syndrome caused by abnormalities in the PTCH gene.  It is characterized by multiple basal cell carcinomas at a young age, odontogenic keratocysts, and skeletal defects (bifurcated and splayed ribs, fusion of vertebrae, spinal bifida).  Patients with this syndrome may also develop medulloblastomas and ovarian fibromas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nevoid Basal Cell Carcinoma Syndrome","conceptCode":"C2892","definition":"An autosomal dominant genetic syndrome caused by abnormalities in the PTCH and SUFU gene. It is characterized by multiple basal cell carcinomas at a young age, odontogenic keratocysts, and skeletal defects (bifurcated and splayed ribs, fusion of vertebrae, spinal bifida). Patients with this syndrome may also develop medulloblastomas and ovarian fibromas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-B1D8-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B49F37E-E0AA-074D-E053-F662850AC0B0","beginDate":"2017-10-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-10-11","modifiedBy":"ONEDATA","dateModified":"2017-10-11","deletedIndicator":"No"},{"value":"Rubinstein-Taybi syndrome","valueDescription":"Rubinstein-Taybi Syndrome","ValueMeaning":{"publicId":"3211427","version":"1","preferredName":"Rubinstein-Taybi Syndrome","longName":"3211427","preferredDefinition":"A rare genetic syndrome mapped to chromosome 16p13.3 and associated with mutations in the CREBBP gene.  It is characterized by mental and growth retardation, distinctive facial features (prominent nose, low-set ears, microcephaly, and small mouth), and broad thumbs and great toes.  Patients are at an increased risk of developing benign and malignant neoplasms, including nervous system neoplasms and malignant lymphoproliferative disorders.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Rubinstein-Taybi Syndrome","conceptCode":"C75466","definition":"A rare genetic syndrome mapped to chromosome 16p13.3 and associated with mutations in the CREBBP gene. It is characterized by mental and growth retardation, distinctive facial features (prominent nose, low-set ears, microcephaly, and small mouth), and broad thumbs and great toes. Patients are at an increased risk of developing benign and malignant neoplasms, including nervous system neoplasms and malignant lymphoproliferative disorders.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-FC39-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B49F37E-E0BF-074D-E053-F662850AC0B0","beginDate":"2017-10-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-10-11","modifiedBy":"ONEDATA","dateModified":"2017-10-11","deletedIndicator":"No"},{"value":"Not Applicable ","valueDescription":"Not Applicable","ValueMeaning":{"publicId":"5682946","version":"1","preferredName":"Not Applicable","longName":"5682946v1.00","preferredDefinition":"Determination of a value is not relevant in the current context.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Applicable","conceptCode":"C48660","definition":"Determination of a value is not relevant in the current context.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B0E12-9B2B-79DC-E053-F662850A0B75","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"MMADDINENI","dateModified":"2024-02-20","changeDescription":null,"administrativeNotes":"2023.8.15 Alt VM added per ticket request CADSR0002731. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B49F37E-E0D4-074D-E053-F662850AC0B0","beginDate":"2017-10-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-10-11","modifiedBy":"ONEDATA","dateModified":"2017-10-11","deletedIndicator":"No"},{"value":"Unknown ","valueDescription":"Unknown","ValueMeaning":{"publicId":"2572577","version":"1","preferredName":"Unknown","longName":"2572577","preferredDefinition":"Not known, not observed, not recorded, or refused.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E88E-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-12-30","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2004-12-30","modifiedBy":"COLBERTM","dateModified":"2023-09-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B49F37E-E0DF-074D-E053-F662850AC0B0","beginDate":"2017-10-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-10-11","modifiedBy":"ONEDATA","dateModified":"2017-10-11","deletedIndicator":"No"},{"value":"Turcot syndrome","valueDescription":"Turcot Syndrome","ValueMeaning":{"publicId":"6002212","version":"1","preferredName":"Turcot Syndrome","longName":"6002212","preferredDefinition":"An autosomal dominant hereditary neoplastic syndrome caused by mutations in the PMS2, MLH1, MSH2, or APC genes. There are two types described, type 1, characterized by the presence of glioblastoma and often associated with hereditary nonpolyposis colorectal carcinoma, and type 2, characterized by the presence of medulloblastoma and familiar adenomatous polyposis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Turcot Syndrome","conceptCode":"C3938","definition":"An autosomal dominant hereditary neoplastic syndrome caused by mutations in the PMS2, MLH1, MSH2, or APC genes. There are two types described, type 1, characterized by the presence of glioblastoma and often associated with hereditary nonpolyposis colorectal carcinoma, and type 2, characterized by the presence of medulloblastoma and familiar adenomatous polyposis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B4E1CD4-4E37-160D-E053-F662850A7005","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-10-11","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"5B4E1CD4-4E50-160D-E053-F662850A7005","beginDate":"2017-10-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-10-11","modifiedBy":"ONEDATA","dateModified":"2017-10-11","deletedIndicator":"No"},{"value":"Cirrhosis unknown etiology","valueDescription":"Cirrhosis Unknown Etiology","ValueMeaning":{"publicId":"6133539","version":"1","preferredName":"Cirrhosis Unknown Etiology","longName":"6133539","preferredDefinition":"A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.: Not known, not observed, not recorded, or refused.: The cause of a disease or abnormal condition.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cirrhosis","conceptCode":"C2951","definition":"A disorder characterized by replacement of the liver parenchyma with fibrous tissue and regenerative nodules. It is usually caused by alcoholism, hepatitis B, and hepatitis C. Complications include the development of ascites, esophageal varices, bleeding, and hepatic encephalopathy.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Etiology","conceptCode":"C16390","definition":"The cause of a disease or abnormal condition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6761AD03-D2AF-3644-E053-F662850AD35A","latestVersionIndicator":"Yes","beginDate":"2018-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-14","modifiedBy":"ONEDATA","dateModified":"2018-03-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6761AD03-D2C8-3644-E053-F662850AD35A","beginDate":"2018-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-14","modifiedBy":"ONEDATA","dateModified":"2018-03-14","deletedIndicator":"No"},{"value":"Alpha-1 antitrypsin","valueDescription":"Alpha-1 Antitrypsin Deficiency","ValueMeaning":{"publicId":"3171840","version":"1","preferredName":"Alpha-1 Antitrypsin Deficiency","longName":"3171840","preferredDefinition":"A genetic disorder characterized by decreased alpha-1 antitrypsin activity in the lungs and blood and deposition of alpha-1 antitrypsin protein in the hepatocytes. These abnormalities result from defective production of alpha-1 antitrypsin and lead to the development of emphysema, cirrhosis, and liver failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Alpha-1 Antitrypsin Deficiency","conceptCode":"C84397","definition":"A genetic disorder characterized by decreased alpha-1 antitrypsin activity in the lungs and blood and deposition of alpha-1 antitrypsin protein in the hepatocytes. These abnormalities result from defective production of alpha-1 antitrypsin and lead to the development of emphysema, cirrhosis, and liver failure.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"97DDA7EA-0146-07E7-E040-BB89AD4351C6","latestVersionIndicator":"Yes","beginDate":"2010-12-20","endDate":null,"createdBy":"WHITES","dateCreated":"2010-12-20","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6761AD03-D2D2-3644-E053-F662850AD35A","beginDate":"2018-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-14","modifiedBy":"ONEDATA","dateModified":"2018-03-14","deletedIndicator":"No"},{"value":"Beckwith-Wiedemann","valueDescription":"Beckwith-Wiedemann Syndrome","ValueMeaning":{"publicId":"2967368","version":"1","preferredName":"Beckwith-Wiedemann Syndrome","longName":"2967368","preferredDefinition":"A genetic syndrome caused by abnormalities in chromosome 11.  It is characterized by large birth weight, macroglossia, umbilical hernia, ear abnormalities, and hypoglycemia.  Patients with this syndrome have an increased risk of developing embryonal tumors (gonadoblastoma, hepatoblastoma, Wilms tumor, Rhabdomyosarcoma) and adrenal cortex carcinomas.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Beckwith-Wiedemann Syndrome","conceptCode":"C34415","definition":"A genetic syndrome caused by abnormalities in chromosome 11. It is characterized by large birth weight, macroglossia, umbilical hernia, ear abnormalities, and hypoglycemia. Patients with this syndrome have an increased risk of developing embryonal tumors (gonadoblastoma, hepatoblastoma, Wilms tumor, rhabdomyosarcoma) and adrenal cortex carcinomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7AB32307-57DC-1A4F-E040-BB89AD43618C","latestVersionIndicator":"Yes","beginDate":"2009-12-14","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-12-14","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6761AD03-D2DD-3644-E053-F662850AD35A","beginDate":"2018-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-14","modifiedBy":"ONEDATA","dateModified":"2018-03-14","deletedIndicator":"No"},{"value":"Biliary disorder","valueDescription":"Biliary Tract Disorder","ValueMeaning":{"publicId":"3210777","version":"1","preferredName":"Biliary Tract Disorder","longName":"3210777","preferredDefinition":"A non-neoplastic or neoplastic disorder affecting the intrahepatic or extrahepatic biliary tract. Examples of non-neoplastic disorders include infection and atresia. Examples of neoplastic disorders include adenoma and carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Biliary System Disorder","conceptCode":"C2899","definition":"A non-neoplastic or neoplastic disorder that affects the intrahepatic or extrahepatic bile ducts or the gallbladder. Representative examples of non-neoplastic disorders include cholangitis and cholecystitis. Representative examples of neoplastic disorders include extrahepatic bile duct adenoma, intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-9DF0-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SOKKERL","dateModified":"2023-10-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6761AD03-D2F1-3644-E053-F662850AD35A","beginDate":"2018-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-14","modifiedBy":"ONEDATA","dateModified":"2018-03-14","deletedIndicator":"No"},{"value":"Glycogen Storage Disease","valueDescription":"Glycogen Storage Disease","ValueMeaning":{"publicId":"2593481","version":"1","preferredName":"Glycogen Storage Disease","longName":"2593481","preferredDefinition":"An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glycogen Storage Disease","conceptCode":"C61272","definition":"An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BD3AD6-BCD6-64E1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6761AD03-D2FC-3644-E053-F662850AD35A","beginDate":"2018-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-14","modifiedBy":"ONEDATA","dateModified":"2018-03-14","deletedIndicator":"No"},{"value":"Tyrosinemia","valueDescription":"Tyrosinemia","ValueMeaning":{"publicId":"6013366","version":"1","preferredName":"Tyrosinemia","longName":"6013366","preferredDefinition":"An autosomal recessive inherited metabolic disorder caused by mutations in the FAH, HPD, and TAT genes. It is characterized by deficiency of one of the enzymes that are involved in the metabolism of tyrosine. It results in elevated blood tyrosine levels and accumulation of tyrosine and its byproducts in the liver, kidney, nervous system and other organs.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tyrosinemia","conceptCode":"C98640","definition":"An autosomal recessive inherited metabolic disorder caused by mutations in the FAH, HPD, and TAT genes. It is characterized by deficiency of one of the enzymes that are involved in the metabolism of tyrosine. It results in elevated blood tyrosine levels and accumulation of tyrosine and its byproducts in the liver, kidney, nervous system and other organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"5CD9A0AB-573B-70DD-E053-F662850A7724","latestVersionIndicator":"Yes","beginDate":"2017-10-31","endDate":null,"createdBy":"COOPERM","dateCreated":"2017-10-31","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6761AD03-D307-3644-E053-F662850AD35A","beginDate":"2018-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-14","modifiedBy":"ONEDATA","dateModified":"2018-03-14","deletedIndicator":"No"},{"value":"Not Reported","valueDescription":"Not Reported","ValueMeaning":{"publicId":"2572231","version":"1","preferredName":"Not Reported","longName":"2572231","preferredDefinition":"Not provided or available.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Reported","conceptCode":"C43234","definition":"Not provided or available.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-E734-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2004-11-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2004-11-16","modifiedBy":"CLOHNES","dateModified":"2023-11-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6761AD03-D312-3644-E053-F662850AD35A","beginDate":"2018-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-14","modifiedBy":"ONEDATA","dateModified":"2018-03-14","deletedIndicator":"No"},{"value":"Hereditary renal oncocytoma","valueDescription":"Hereditary Kidney Oncocytoma","ValueMeaning":{"publicId":"6789677","version":"1","preferredName":"Hereditary Kidney Oncocytoma","longName":"6789677","preferredDefinition":"An inherited condition characterized by the development of kidney oncocytomas which are often bilateral and multifocal.  This condition may be connected to Birt-Hogg-Dube syndrome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hereditary Kidney Oncocytoma","conceptCode":"C8960","definition":"An inherited condition characterized by the development of kidney oncocytomas which are often bilateral and multifocal.  This condition may be connected to Birt-Hogg-Dube syndrome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C154154-4FCC-48BD-E053-F662850A2BF9","latestVersionIndicator":"Yes","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"ONEDATA","dateModified":"2019-06-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C19356C-F2A9-4E69-E053-F662850A4390","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"ONEDATA","dateModified":"2019-06-24","deletedIndicator":"No"},{"value":"Tuberous sclerosis","valueDescription":"Tuberous Sclerosis","ValueMeaning":{"publicId":"2962075","version":"1","preferredName":"Tuberous Sclerosis","longName":"2962075","preferredDefinition":"Hereditary disease characterized by seizures, mental retardation, developmental delay, and skin and ocular lesions. First signs usually occur during infancy or childhood but in rare cases may not occur until 2nd or 3rd decade.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Tuberous Sclerosis","conceptCode":"C3424","definition":"Hereditary disease characterized by seizures, mental retardation, developmental delay, and skin and ocular lesions. First signs usually occur during infancy or childhood but in rare cases may not occur until 2nd or 3rd decade.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78BA0E7A-4A1B-2225-E040-BB89AD436E34","latestVersionIndicator":"Yes","beginDate":"2009-11-19","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-11-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C19356C-F2B3-4E69-E053-F662850A4390","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"ONEDATA","dateModified":"2019-06-24","deletedIndicator":"No"},{"value":"Familial renal cancer","valueDescription":"Hereditary Renal Cell Carcinoma","ValueMeaning":{"publicId":"6789679","version":"1","preferredName":"Hereditary Renal Cell Carcinoma","longName":"6789679","preferredDefinition":"Renal cell carcinoma that has developed in relatives of patients with history of renal cell carcinoma.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hereditary Renal Cell Carcinoma","conceptCode":"C39789","definition":"Renal cell carcinoma that has developed in relatives of patients with history of renal cell carcinoma.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C154154-4FFD-48BD-E053-F662850A2BF9","latestVersionIndicator":"Yes","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"ONEDATA","dateModified":"2019-06-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C19356C-F2BD-4E69-E053-F662850A4390","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"ONEDATA","dateModified":"2019-06-24","deletedIndicator":"No"},{"value":"Birt-Hogg-Dube syndrome","valueDescription":"Birt-Hogg-Dube Syndrome","ValueMeaning":{"publicId":"6789681","version":"1","preferredName":"Birt-Hogg-Dube Syndrome","longName":"6789681","preferredDefinition":"A rare genetic syndrome with an autosomal dominant pattern of inheritance. It is caused by a mutation in the FLCN gene which encodes the protein folliculin. Clinical signs include multiple benign growths of the skin and lungs that begin to manifest in the second or third decade of life. The clinical course is characterized by the progressive growth of new and existing neoplasms. In those with mutations in both copies of FLCN, the kidneys may also be affected by the growth of benign or malignant neoplasms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Birt-Hogg-Dube Syndrome","conceptCode":"C28244","definition":"A rare genetic syndrome with an autosomal dominant pattern of inheritance. It is caused by a mutation in the FLCN gene which encodes the protein folliculin. Clinical signs include multiple benign growths of the skin and lungs that begin to manifest in the second or third decade of life. The clinical course is characterized by the progressive growth of new and existing neoplasms. In those with mutations in both copies of FLCN, the kidneys may also be affected by the growth of benign or malignant neoplasms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C154154-5023-48BD-E053-F662850A2BF9","latestVersionIndicator":"Yes","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"ONEDATA","dateModified":"2019-06-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C19356C-F2C7-4E69-E053-F662850A4390","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"ONEDATA","dateModified":"2019-06-24","deletedIndicator":"No"},{"value":"Hereditary leiomyoma-renal cell carcinoma","valueDescription":"Hereditary Leiomyomatosis and Renal Cell Cancer","ValueMeaning":{"publicId":"6789030","version":"1","preferredName":"Hereditary Leiomyomatosis and Renal Cell Cancer","longName":"6789030","preferredDefinition":"An autosomal dominant inherited syndrome caused by germline mutations in the FH gene. It is characterized by predisposition to leiomyomas of the skin and uterus, renal cell carcinoma, and leiomyosarcoma of the uterus.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hereditary Leiomyomatosis and Renal Cell Carcinoma","conceptCode":"C51302","definition":"An autosomal dominant inherited syndrome caused by germline mutations in the FH gene. It is characterized by predisposition to renal cell carcinoma, leiomyomas of the skin and uterus, and leiomyosarcoma of the uterus.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8BDAECC9-DB33-02E9-E053-F662850AABB5","latestVersionIndicator":"Yes","beginDate":"2019-06-21","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-21","modifiedBy":"ONEDATA","dateModified":"2019-06-21","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C19356C-F2D1-4E69-E053-F662850A4390","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"ONEDATA","dateModified":"2019-06-24","deletedIndicator":"No"},{"value":"Hereditary papillary renal cell carcinoma","valueDescription":"Hereditary Papillary Renal Cell Carcinoma","ValueMeaning":{"publicId":"3248532","version":"1","preferredName":"Hereditary Papillary Renal Cell Carcinoma","longName":"3248532","preferredDefinition":"A familiar carcinoma inherited in an autosomal dominant trait.  It is characterized by the development of multiple, bilateral papillary renal cell carcinomas.  The carcinomas range from microscopic lesions to clinically symptomatic tumors.  It is associated with activating mutations of the MET oncogene.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hereditary Papillary Renal Cell Carcinoma","conceptCode":"C9222","definition":"A familial carcinoma inherited in an autosomal dominant trait.  It is characterized by the development of multiple, bilateral papillary renal cell carcinomas.  The carcinomas range from microscopic lesions to clinically symptomatic tumors.  It is associated with activating mutations of the MET oncogene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A6BBE041-B9AC-9503-E040-BB89AD435A00","latestVersionIndicator":"Yes","beginDate":"2011-06-27","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-06-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C19356C-F2DB-4E69-E053-F662850A4390","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"ONEDATA","dateModified":"2019-06-24","deletedIndicator":"No"},{"value":"SDH associated renal cancer","valueDescription":"Associated SDH Complex Gene Mutation Kidney Carcinoma","ValueMeaning":{"publicId":"6789682","version":"1","preferredName":"Associated SDH Complex Gene Mutation Kidney Carcinoma","longName":"6789682","preferredDefinition":"Joined in some kind of relationship.: A change in the nucleotide sequence of any gene that encodes one of the proteins in the succinate dehydrogenase (SDH) complex.: A carcinoma arising from the epithelium of the renal parenchyma or the renal pelvis.  The majority are renal cell carcinomas.  Kidney carcinomas usually affect middle aged and elderly adults.  Hematuria, abdominal pain, and a palpable mass are common symptoms.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Associated","conceptCode":"C25281","definition":"Joined in some kind of relationship.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"SDH Complex Gene Mutation","conceptCode":"C48301","definition":"A change in the nucleotide sequence of any gene that encodes one of the proteins in the succinate dehydrogenase (SDH) complex.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Kidney Carcinoma","conceptCode":"C9384","definition":"A carcinoma arising from the epithelium of the renal parenchyma or the renal pelvis.  The majority are renal cell carcinomas.  Kidney carcinomas usually affect middle aged and elderly adults.  Hematuria, abdominal pain, and a palpable mass are common symptoms.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C154154-5074-48BD-E053-F662850A2BF9","latestVersionIndicator":"Yes","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"ONEDATA","dateModified":"2019-06-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C19356C-F2E5-4E69-E053-F662850A4390","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"ONEDATA","dateModified":"2019-06-24","deletedIndicator":"No"},{"value":"PTEN hamartoma syndrome (Cowden syndrome)","valueDescription":"Cowden Syndrome","ValueMeaning":{"publicId":"3210989","version":"1","preferredName":"Cowden Syndrome","longName":"3210989","preferredDefinition":"An autosomal dominant hereditary syndrome characterized by a variety of hamartomas and neoplasms including verrucous skin lesions, fibromas of the oral cavity, facial trichilemmomas, hamartomatous colonic polyps, thyroid neoplasms, breast cancer, and dysplastic gangliocytomas of the cerebellum.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cowden Syndrome","conceptCode":"C3076","definition":"An autosomal dominant hereditary syndrome characterized by a variety of hamartomas and neoplasms including verrucous skin lesions, fibromas of the oral cavity, facial trichilemmomas, hamartomatous colonic polyps, thyroid neoplasms, breast cancer, and dysplastic gangliocytomas of the cerebellum.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E161-BE3C-C614-E040-BB89AD4377D5","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C19356C-F2EF-4E69-E053-F662850A4390","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"ONEDATA","dateModified":"2019-06-24","deletedIndicator":"No"},{"value":"BAP1 mutant disease","valueDescription":"BAP1 Gene Mutation Disease or Disorder","ValueMeaning":{"publicId":"6789683","version":"1","preferredName":"BAP1 Gene Mutation Disease or Disorder","longName":"6789683","preferredDefinition":"A change in the nucleotide sequence of the BAP1 gene.: Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"BAP1 Gene Mutation","conceptCode":"C128813","definition":"A change in the nucleotide sequence of the BAP1 gene.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8C154154-50AF-48BD-E053-F662850A2BF9","latestVersionIndicator":"Yes","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"ONEDATA","dateModified":"2019-06-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C19356C-F2F9-4E69-E053-F662850A4390","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"ONEDATA","dateModified":"2019-06-24","deletedIndicator":"No"},{"value":"von Hippel-Lindau Syndrome","valueDescription":"Von Hippel-Lindau Syndrome","ValueMeaning":{"publicId":"2962084","version":"1","preferredName":"Von Hippel-Lindau Syndrome","longName":"2962084","preferredDefinition":"An inherited familial cancer syndrome which is characterized by development of capillary hemangioblastomas of the central nervous system and retina; clear cell renal carcinoma; pheochromocytoma; pancreatic tumors; and inner ear tumors. The syndrome is associated with germline mutations of the VHL tumor suppressor gene, located on chromosome 3p25-26. Symptoms of VHL syndrome may not be apparent until the third decade of life. CNS hemangioblastoma is the most common cause of death, followed by clear cell renal cell carcinoma. --2004","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Von Hippel Lindau Syndrome","conceptCode":"C3105","definition":"An inherited familial cancer syndrome which is characterized by development of capillary hemangioblastomas of the central nervous system and retina; clear cell renal carcinoma; pheochromocytoma; pancreatic tumors; and inner ear tumors. The syndrome is associated with germline mutations of the VHL tumor suppressor gene, located on chromosome 3p25-26. Symptoms of VHL syndrome may not be apparent until the third decade of life. CNS hemangioblastoma is the most common cause of death, followed by clear cell renal cell carcinoma. --2004","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"78BA0E7A-4AD9-2225-E040-BB89AD436E34","latestVersionIndicator":"Yes","beginDate":"2009-11-19","endDate":null,"createdBy":"ZHANGW","dateCreated":"2009-11-19","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8C19356C-F30D-4E69-E053-F662850A4390","beginDate":"2019-06-24","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2019-06-24","modifiedBy":"ONEDATA","dateModified":"2019-06-24","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435022","version":"1","preferredName":"Disease, Disorder or Finding","preferredDefinition":"Specification of human conditions relevant to cancer. This includes observations, test results, history, and other concepts relevant to characterization of human cancer-related conditions. Non-neoplastic conditions of interest are also included.","longName":"C7057","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"0741B16D-87D9-26CD-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"HCMI:Human Cancer Models Initiative","workflowStatus":"RELEASED","registrationStatus":"Application","id":"5B49F37E-E068-074D-E053-F662850AC0B0","latestVersionIndicator":"Yes","beginDate":"2017-10-11","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2017-10-11","modifiedBy":"HARTLEYG","dateModified":"2019-06-24","changeDescription":"Curated to support HCMI Brain Tumor_110.11.17_ghd","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5428034","version":"1","longName":"Clinical","context":"GDC","ClassificationSchemeItems":[{"publicId":"6059563","version":"1","longName":"Followup","context":"GDC"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Genetic syndrome diagnoses","type":"Preferred Question Text","description":"Genetic syndrome diagnoses","url":null,"context":"GDC"}],"origin":"GDC:NCI Genomic Data Commons","workflowStatus":"RELEASED","registrationStatus":"Application","id":"676689F5-F3A6-0AEE-E053-F662850A6B59","latestVersionIndicator":"Yes","beginDate":"2018-03-14","endDate":null,"createdBy":"COOPERM","dateCreated":"2018-03-14","modifiedBy":"KNABLEJ","dateModified":"2022-03-16","changeDescription":"3/16/22 jk Quarterly AI review. Released, reuse of shared DEC. 3.8.18 mc Created for caDSR Requests Q12018 Dictionary Updates for Review","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}